Nyxoah Wins the 2026 UK Galien Award for its Genio Sleep Apnea Therapy
On Monday, Nyxoah received the 2026 UK Galien Award for its Genio technology, a hypoglossal nerve stimulation therapy aimed at treating obstructive sleep apnea. This award comes amid commercial growth in Europe and the United States, where the company recently completed a funding round.
Genio Recognized as a Major Health Innovation
The Genio system was awarded as the best medical technology at the 2026 UK Galien Awards, a prestigious distinction in the health industry. The award honors innovations that bring significant advancements in treatment and improve the quality of life for patients. Specifically, Genio addresses obstructive sleep apnea, a chronic condition affecting millions and associated with increased risks of cardiovascular diseases, metabolic disorders, and diminished quality of life. Olivier Taelman, CEO of Nyxoah, emphasized that this recognition reflects the collective effort of engineers, customer support teams, physicians who implement the therapy, and patients who have trusted the technology.
Sustained Commercial Momentum in the UK and Beyond
In the UK, the award highlights the commitment of a growing team collaborating with partners in the public health system (NHS) and the private sector to expand access to innovative therapeutic options. This recognition comes during a period of acceleration for Nyxoah, marked by FDA approval and the commercial launch of the system in the United States, coupled with strengthened funding announced in June to accelerate the American deployment. The adoption of the Genio system continues to progress in Europe and other international markets.
